标题
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 19, Issue 1, Pages 51-69
出版商
Springer Science and Business Media LLC
发表日期
2021-10-06
DOI
10.1038/s41571-021-00558-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Subtypes of EGFR and HER2 mutant metastatic NSCLC influence response to immune checkpoint inhibitors
- (2021) Sally CM. Lau et al. Clinical Lung Cancer
- 36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
- (2021) A. Sacher et al. ANNALS OF ONCOLOGY
- Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions
- (2021) Noura J. Choudhury et al. CLINICAL CANCER RESEARCH
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
- (2021) Gregory J. Riely et al. Cancer Discovery
- Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
- (2021) Francois Gonzalvez et al. Cancer Discovery
- HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
- (2021) Said A. Khelwatty et al. Cancers
- Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
- (2021) Shuo Yang et al. Translational Lung Cancer Research
- Immunotherapy in non-small cell lung cancer harbouring driver mutations
- (2021) Alfredo Addeo et al. CANCER TREATMENT REVIEWS
- Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
- (2021) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
- (2021) C. Zhou et al. Journal of Thoracic Oncology
- Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
- (2021) Han Han et al. CANCER RESEARCH
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.
- (2021) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.
- (2021) Alison M. Schram et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.
- (2021) Bianca van Veggel et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).
- (2021) Zofia Piotrowska et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
- (2021) Julien Mazieres et al. JOURNAL OF CLINICAL ONCOLOGY
- Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
- (2021) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.
- (2021) Catherine A. Shu et al. JOURNAL OF CLINICAL ONCOLOGY
- A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers
- (2021) Ranpu Wu et al. Journal of Thoracic Disease
- Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions
- (2020) Russell W. Madison et al. BJU INTERNATIONAL
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.
- (2020) Florian Guisier et al. Journal of Thoracic Oncology
- Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
- (2020) Shen Zhao et al. Journal of Thoracic Oncology
- TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
- (2020) Julia Roeper et al. Oncotarget
- Molecular profiling for precision cancer therapies
- (2020) Eoghan R. Malone et al. Genome Medicine
- Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis
- (2020) Haijing Liu et al. Cancer Communications
- Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
- (2020) Philip C. Mack et al. CANCER
- The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
- (2020) Valerio Gristina et al. CANCER TREATMENT REVIEWS
- Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
- (2020) Iosune Baraibar et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.
- (2020) Zofia Piotrowska et al. JOURNAL OF CLINICAL ONCOLOGY
- Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
- (2020) Xiuning Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
- (2020) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.
- (2020) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.
- (2020) Binghe Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
- (2020) Guangjian Yang et al. LUNG CANCER
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- (2020) Junji Tsurutani et al. Cancer Discovery
- Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
- (2020) Qitong Chen et al. Frontiers in Oncology
- New therapeutic approaches to overcoming resistant EGFR exon 20 alterations
- (2020) Alex M. Li et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
- (2020) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
- (2020) Xinyong Zhang et al. Frontiers in Oncology
- 1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
- (2020) A. Prelaj et al. ANNALS OF ONCOLOGY
- 11P Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions
- (2020) Y. Nagamoto et al. ANNALS OF ONCOLOGY
- LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
- (2020) M.A. Socinski et al. ANNALS OF ONCOLOGY
- LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
- (2020) S.V. Liu et al. ANNALS OF ONCOLOGY
- A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
- (2020) Benjamin C. Creelan et al. BRITISH JOURNAL OF CANCER
- Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403
- (2020) Sarah B. Goldberg et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib
- (2020) Niamh Coleman et al. Journal of Thoracic Oncology
- Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
- (2020) Adriana Estrada-Bernal et al. CLINICAL CANCER RESEARCH
- Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
- (2020) Kaiyan Chen et al. Thoracic Cancer
- A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
- (2020) Ziteng Li et al. EBioMedicine
- Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
- (2019) Alessandro Russo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
- (2019) Alex Friedlaender et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- A Patient with EGFR Exon 20 Insertion–Mutant Non–Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy
- (2019) Wenfeng Fang et al. Journal of Thoracic Oncology
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- 1529PPhase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
- (2019) T M Kim et al. ANNALS OF ONCOLOGY
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- (2019) Jacqulyne P. Robichaux et al. CANCER CELL
- Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation
- (2019) Wenfeng Fang et al. Journal of Thoracic Oncology
- P2.01-51 Next-Generation Sequencing for Effective Detection of Various EGFR Exon 20 Insertions (E20ins) in Non-Small Cell Lung Cancer (NSCLC)
- (2019) I. Hwang et al. Journal of Thoracic Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
- (2019) Lillian M. Smyth et al. Cancer Discovery
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer
- (2018) Namita Sharma et al. CANCER TREATMENT REVIEWS
- Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
- (2018) Alfredo Addeo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC
- (2018) Bianca van Veggel et al. Journal of Thoracic Oncology
- Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer
- (2018) Jonathan W. Riess et al. Journal of Thoracic Oncology
- A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
- (2018) Tomomi Nakayama Iwata et al. MOLECULAR CANCER THERAPEUTICS
- TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
- (2018) Shinichi Hasako et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes
- (2018) Su Yudong et al. Thoracic Cancer
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
- (2018) Marcelo Vailati Negrao et al. JOURNAL OF CLINICAL ONCOLOGY
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
- (2018) Y Wang et al. ANNALS OF ONCOLOGY
- Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
- (2018) Apurva Pandey et al. Clinical Breast Cancer
- Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
- (2018) Dhivya R. Sudhan et al. CLINICAL CANCER RESEARCH
- EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)
- (2018) Andrés F. Cardona et al. LUNG CANCER
- Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
- (2018) Hanako Hasegawa et al. LUNG CANCER
- Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
- (2018) Sandra Rayego-Mateos et al. MEDIATORS OF INFLAMMATION
- Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2017) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- OA 12.02 Final Results of a Phase 2 Study of the hsp90 Inhibitor Luminespib (AUY922) in NSCLC Patients Harboring EGFR Exon 20 Insertions
- (2017) Z. Piotrowska et al. Journal of Thoracic Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- (2017) Ken Uchibori et al. Nature Communications
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
- (2017) Endang Purba et al. Cells
- LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY
- (2017) B. Besse et al. ANNALS OF ONCOLOGY
- Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
- (2016) J L Kuiper et al. BRITISH JOURNAL OF CANCER
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas
- (2016) Daniel B. Costa et al. Journal of Thoracic Oncology
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2015) Gideon M. Blumenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Maximizing the Therapeutic Potential of HSP90 Inhibitors
- (2015) L. M. Butler et al. MOLECULAR CANCER RESEARCH
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
- (2015) Igor F. Tsigelny et al. Oncotarget
- Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
- (2014) Hye Ryun Kim et al. LUNG CANCER
- HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations
- (2014) Akihiko Yoshizawa et al. LUNG CANCER
- Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
- (2013) M. Beau-Faller et al. ANNALS OF ONCOLOGY
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection ofEGFR,KRAS,andBRAFMutations on Formalin-Fixed, Paraffin-Embedded Tumor Material of Non-Small Cell Lung Carcinoma-Superiority of NGS
- (2013) Katja Tuononen et al. GENES CHROMOSOMES & CANCER
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
- (2013) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
- (2013) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations
- (2013) J. J. Wheler et al. MOLECULAR CANCER THERAPEUTICS
- EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter
- (2013) Pei Jye Voon et al. MOLECULAR CANCER THERAPEUTICS
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry
- (2012) Bárbara Angulo et al. PLoS One
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
- (2011) Toni M. Brand et al. CANCER BIOLOGY & THERAPY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- An integrated semiconductor device enabling non-optical genome sequencing
- (2011) Jonathan M. Rothberg et al. NATURE
- Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
- (2010) Takeshi Yoshida et al. BIOCHEMICAL PHARMACOLOGY
- Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer
- (2010) A. Kitamura et al. CLINICAL CANCER RESEARCH
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
- (2009) Michael J. Eck et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
- (2009) S. A. Perera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now